Product portfolio

Blood clots affect many major organs and new drugs that show positive effects can build their “portfolio” of indications / uses as long as continued investments in product documentation are done.

In Cereno Scientific’s case, the possible indications for treatment are many, in addition to the initial applications in various forms of venous thrombosis and pulmonary embolism, the goal is the prevention of heart attacks and strokes that today are the largest causes of death worldwide.